Differential evolution of cell-associated virus in blood and genital tract of HIV-infected females undergoing HAART  by Tirado, Grissell et al.
www.elsevier.com/locate/yviroVirology 334 (20Differential evolution of cell-associated virus in blood and genital
tract of HIV-infected females undergoing HAART
Grissell Tiradoa,b, Gloria Jovec, Evelyn Reyesd, Gladys Sepulvedae, Yasuhiro Yamamurab,c,
Dhirendra P. Singhf, Anil Kumara,b,c,T
aLaboratory of Viral Immunology, Ponce School of Medicine, Ponce, Puerto Rico 00732
bAIDS Research Program, Ponce School of Medicine, Ponce, Puerto Rico 00732
cDepartment of Microbiology, Ponce School of Medicine, Ponce, Puerto Rico 00732
dDepartment of Health Immunology Clinic, Arecibo, USA
eDepartment of Health Immunology Clinic, Ponce, Puerto Rico 00731
fUniversity of Nebraska Medical Center, Omaha, NE 68198-5840, USA
Received 29 September 2004; returned to author for revision 17 November 2004; accepted 26 January 2005Abstract
PBMC and vaginal cell (VC) viruses were studied from 5 HIV-infected females for the presence of drug-resistance and non-drug
resistance associated mutations. A 1318-bp fragment of polymerase gene was amplified from PBMC and VC proviral DNA. Four of the 5
PBMC viruses exhibited drug resistance-associated mutations in reverse transcriptase and protease genes, whereas only 2 VC viruses
contained drug resistance-associated mutations. However, all 5 females showed non-drug resistance-associated mutations both in PBMC and
VC virus suggesting continuous evolution of the virus in these compartments. The emergence of drug resistance was slower in PBMC and
VC viruses than that observed in the cell-free plasma (P) and vaginal secretion (VS) viruses. Phylogenetic analysis revealed that VC virus
was closer to PBMC virus than either cell-free viruses (P and VS) suggesting comparable evolution among cell-associated viruses.
D 2005 Elsevier Inc. All rights reserved.
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The human immunodeficiency virus type-1 (HIV-1) is
predominantly spread by heterosexual transmission with
the genital mucosa serving as a site of the initial contact.
Therefore, the study of the virus genotype in male and
female genital compartments is critical to the development
of vaccines and treatment strategies. Furthermore, study of
the virus genotype in the female genital compartment may
also offer strategies to block not only the heterosexual
transmission but also mother-to-child transmission. Several
previously reported studies have shown diverse virus0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.01.030
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E-mail address: akumar@psm.edu (A. Kumar).evolution in different anatomical compartments (Kemal et
al., 2003; Wong et al., 1997; Zhu et al., 1996) and the
reason for this may be attributed to the immune and/or
drug pressure leading into development of immune escape
and drug resistant virus. The emergence of drug resistant
virus can be explained on the basis of diverse pharmaco-
kinetic properties (Kepler and Perelson, 1998; Wong et al.,
1997) and poor bioavailability of a particular drug in
different compartments (Lafeuillade et al., 2002). Earlier
studies have mostly demonstrated differential evolution
based on mutations in pol gene in the virus collected from
plasma and cervicovaginal fluid in HIV-infected females
undergoing highly active antiretroviral therapy (De Pas-
quale et al., 2003; Tirado et al., 2004). However, there is
no report available on drug-resistance and non-drug
resistance-associated mutations in pol of cell-associated05) 299–305
Table 1













Anti-retroviral drug historye Current treatment
012 46/H 1994 yes 22 N750,000 96,781 2001: d4T, 3TC, IDV, SQV d4T + 3TC + LPV/RTV
36E 39/H 1993 no 1088 15,749 450 1990: AZT, ddC, ddI, d4T, 3TC,
RTV, IDV, NFV
d4T + 3TC + NFV
41J 39/H 1996 yes 206 24,022 918 1996: AZT, ddC, ddI, d4T, 3TC,
IDV, NFV, SQV
EFV +3TC + d4T
43L 40/H 1987 yes 64 N750,000 NA 2000: 3TC, ddI, d4T, EFV 3TC, d4T, EFV
004 51/H 1997 yes 382 42,322 11,798 1997: 3TC, d4T, RTV, NFV, AZT APV + EFV + ddI
a Risk Factor H = Heterosexual.
b Percent CD4 T cell counts were determined by flowcytometry and Absolute CD4 T cell counts were calculated by multiplying the CD4 T cell percentage with
absolute lymphocyte count.
c Plasma viral load (VL) was determined by Amplicor assay (Roche Diagnostic).
d Vaginal viral RNA load was determined by Amplicor assay (Roche Diagnostic). Since vaginal secretion was diluted 8.5 times, therefore Viral load in vaginal
fluid is expressed as assay value  8.5.
e Antiretroviral used in the study. d4T, stavudine; 3TC, lamiduvine; IDV, indinavir; AZT, zidovudine; NFV, nelfinavir; ddC, zalcitabine; ddI, didanosine; RTV,
ritonavir; SQV, saquinavir; EFV, efavirenz; LPV, lopinavir.
G. Tirado et al. / Virology 334 (2005) 299–305300virus in blood and vaginal compartments. In this study, we
examined 5 HIV-infected females for drug resistance
pattern in peripheral blood mononuclear cells (PBMC)
and vaginal cells (VC) for the emergence of drug-
resistance and also mutation in other regions of protease
and reverse transcriptase.Table 2
Comparison of drug resistance-associated mutations in reverse transcriptase and p
Patient Virus Amino acid position and identification
REVERSE TRANSCRIPTASE 41 44 62 65 67
M E A K D
012 PBMC – – – – –
VC – – – – –
36E PBMC – – A – ND
VC – – – – –
41J PBMC – – – – –
VC – – – K –
43L PBMC – – – – ND
VC – – – – –
004 PBMC – – A – –
VC – – – – –
PROTEASE 10 20 24 30 32
L K L D V
012 PBMC – K – – –
VC – K – – –
36E PBMC L – – – –
VC – – – – –
41J PBMC IV – – – –
VC V – – – –
43L PBMC L K – – –
VC L K – N –
004 PBMC V – – – –
VC – – – – –
a The mutations at amino acid level are shown in bold, whereas silent mutations
particular location represents different quasispecies of the virus. The sequence from
LAI (on the top). Dash denotes parent sequence used for comparison.
b Unexpected amino acid polymorphism at a drug resistance site. It has been asso
c K101E has been found to be associated with drug resistance to NNRTIs (LoemResults and discussion
Demographic, clinical and virologic profile of all the
patients have been described previously (Tirado et al., 2004)
except for the patient 004. The demographic, clinical and
virologic profiles of these patients are shown in Table 1.rotease in PBMC and VC virus of HIV-infected femalesa
69 70 74 75 77 98 100 101
T K L V F A L K
– – – – – – – K
– – – – – – L K
D R – – – – – –
– – – – – – – –
– – – – – – L –
– – – – – A – –
– – – – – – – –
– – I S F – – Ec
– – – – – – L –
– – – – – – – –
33 36 46 47 48 50 54 63
L M M I G I I L
– – – – – – – P
– – – – – – – P
– – ML – – – – P
– – – – – – – P
– – – – – – – L
– – – – – – – L
– – – – – – – P
– V – – – – – P
– I – – – – – P
– – – – – – – P
are shown in italics. The sequence showing more than one amino acid at a
HIV-infected females were aligned with representative sequence from HIV-
ciated with in vitro drug resistance in clade C viruses (Loemba et al., 2002).
ba et al., 2002; Lyons et al., 2005).
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associated mutations as 4 of the 5 individuals showed
mutations associated with resistance to one or more drugs,
whereas only 2 (41J and 43L) of the vaginal cell (VC) virus
showed mutations in the region targeted by antiretrovirals
(Table 2). This is in sharp contrast with our earlier findings
wherein we reported that all 4 plasma (P) and vaginal
secretion (VS) viruses showed one or more mutations in the
protease and/or reverse transcriptase genes that was asso-
ciated with drug resistance (Tirado et al., 2004). In addition
the 5th individual (004) also showed P and VS virus
containing more than one drug-resistance-associated muta-
tion (results not shown). The most frequent mutations in the
cell-associated virus included L63P in the protease that was
identified in both PBMC and VC virus from 4 individuals.
However, this mutation has been shown to be not directly
associated with drug resistance (D’Aquila et al., 2003).
Therefore, even in the presence of this mutation, the virus
was still considered wild type. Patient 43L exhibited
maximum mutations wherein PBMC virus had 6 drug
resistance-associated mutations in reverse transcriptase, and
the VC virus had 9 and 5 mutations in reverse transcriptase
and protease genes, respectively. In our earlier study, the
plasma virus from this patient also showed 6 mutations in
the reverse transcriptase (Tirado et al., 2004), but the pattern103 106 108 115 116 118 151 181 184
K V V Y F V Q Y M
– – – – – – – – –
– – – – – – – – –
– – – – – – – – –
– – – – – – – – –
– – – – – – – – MV
Eb – – – – – – – –
N – – – F – – YC MVI
– – I – – I – C –
N – V – F IV – – V
– – V – F – Q – –
71 73 77 82 84 88 90
A G V V I N L
– – – – – – –
– – – – – – –
TA – – – – – –
A – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
V – I – – D –
V – – – V N M
A – – – – – –was different than that observed in the PBMC virus
suggesting differential evolution of drug resistance pattern
in plasma and PBMC virus. Likewise, VC virus also
showed differential pattern of evolution of the drug
resistance pattern than that seen in the VS virus. Based on
our finding with 5 individuals, it can be suggested that viral
evolution follows different course in cell-free and cell-
associated state even in the same anatomical compartments.
This diverse kinetics of emergence of drug-resistance
pattern can be attributed to different pharmacokinetic
properties of the antiretrovirals in various compartments
(Wong et al., 1997). We also noticed that the emergence of
drug-resistance mutation(s) was slower in cell associated
compartments compared to that in the cell-free viruses. The
donor 012 showed wild type PBMC and VC virus in this
study whereas plasma and VF virus from the same donor
had shown 2 drug resistance-associated mutations, reported
in the previous study (Tirado et al., 2004). We do not know
definite reason for the absence of drug-resistance muta-
tion(s) in the cell-associated virus. However, the sample was
collected only few months after initiation of antiretroviral
treatment and the emergence drug-resistance mutation in the
cellular compartments might have been slower than those
seen in cell-free compartments. This phenomenon has also
been observed in our previous report where the emergence188 190 208 210 215 219 225 230 236
Y G H L T K P M P
– – – – – – – – –
– – – – – – – – –
– – – – – Q – – –
– – – – – – – – –
– – – – – – – – –
– – – – – – – – –
– AG – – – – HP – –
– A – W – N P – –
– – – – Y/S – P – –
– – – – – – P – –
G. Tirado et al. / Virology 334 (2005) 299–305302of drug resistance-associate mutation was different in two
different anatomical compartments (Tirado et al., 2004).
Other 2 patients (36E and 004) with wild type VC virus in
this study were shown to contain 9 and 13 drug resistance
mutations in VS virus in the previously reported study
(Tirado et al., 2004), again suggesting slow emergence of
the drug-resistance associated mutations in cellular virus.
On the other hand, the PBMC and VC virus from all 5
individuals showed other mutations in reverse transcriptase
and protease that were not associated with emergence of
drug resistance. These mutations are shown in Table 3.
Even in the cases where PBMC and VC viruses showed
wild phenotype, there were numerous other mutations that
were not associated with drug resistance. The VC virus
from donor 43L exhibited 9 mutations followed by PBMCTable 3
Comparison of non-drug resistance-associated mutations in reverse transcriptase
Patient Virus Amino acid position and identification
REVERSE TRANSCRIPTASE 42 43 45 47 51 53
E K G I G E
012 PBMC E – – – – –
VC E – – I G –
36E PBMC – – G – – –
VC – – – – – –
41J PBMC – – – – – –
VC – R – – – –
43L PBMC – – – – – –
VC – – – – – E
004 PBMC – – – – – –
VC – – G – – –
162 163 167 170 172 173
S S I P R L
012 PBMC S – – P – –
VC – – – P – –
36E PBMC – – – P – –
VC – – – – K –
41J PBMC – – – – – K
VC – – – – – K
43L PBMC S – – P – –
VC – I – – Q
004 PBMC C S – – – –
VC C T – – – –
PROTEASE 5 11 12 13 14 15
L V T I K I
012 PBMC L – – – – –
VC L – – – K IV
36E PBMC – – P – R –
VC – – – – K –
41J PBMC – – – IV – –
VC – – – – – –
43L PBMC – – – – – –
VC – V – – – –
004 PBMC – – – – K –
VC – – – – K –
a The mutations at amino acid level are shown in bold, whereas silent mutations
particular location represents different quasispecies of the virus. The sequence from
LAI (on the top). Dash denotes parent sequence used for comparison.viruses from patient 41J and 004, and VC virus from
patient 012, each containing 7 mutations in the reverse
transcriptase. Likewise, protease was also target of
mutations with 43L VC and 36E PBMC virus exhibited
6 mutations followed by 012 VC virus that had 5
mutations. In reverse transcriptase, there were two regions
which had mutations in most patients. The 122E-K change
in reverse transcriptase was present in 3 PBMC and 2 VC
viruses. Furthermore, both PBMC and VC virus in patient
41J had silent mutation at this position. The 211R-K
mutation in the reverse transcriptase was also present in
both viruses from patient 012 and 41J and also in VC
virus from patient 43L. Likewise, all PBMC and VC virus
exhibited mutation at amino acid position 37 in the
protease gene. The regions encompassing positions 122and protease in PBMC and VC virus of HIV-infected femalesa
60 66 80 82 83 87 89 90 93
V K L K R F E V G
– – – K – F – V –
– – – K – F – V –
I K – – – – – – –
– – – K – F – – –
– – L K K – – – –
– – L K K – – – –
– – – – – – E – G
– – L – – – – – –
– – – – K – – – –
– – – – K – – – –
177 178 179 180 182 186 196 197 198
D I V I Q D G Q H
– – V I – D – Q –
– – V – – D – Q –
– – – – – D – – H
– – – – – – – – –
– – – – – – GV – –
– – – – – – – – –
– – – I – D – Q –
N – – – Q – – Q –
– L – – – – – – H
E – – – – – – – H
17 18 25 31 32 33 35 37 38
G Q D T V L E S L
– – – – – – D E –
– – – – – – D E –
– Q – – – VL – ND L
– Q – – V I – T –
– – – – – – – N –
– – – – – – – N –
– – – T – – – N –
G – – – – – D E –
– Q D – – I D N –
– – – – – I – T –
are shown in italics. The sequence showing more than one amino acid at a
HIV-infected females were aligned with representative sequence from HIV-
G. Tirado et al. / Virology 334 (2005) 299–305 303and 211 in reverse transcriptase and 37 in protease genes
have been identified as CTL epitopes (Altfeld et al., 2001;
Kaul et al., 2001; van der Burg et al., 1997). These results
suggest that immune pressure in tandem with drug
pressure leads to the development of variant viruses, and
a mutation in CTL epitope region will help in the
development of CTL-escape virus. In addition, there were
numerous silent mutations in the reverse transcriptase and
protease genes suggesting that virus evolution was a
continuous phenomenon.
We analyzed the sequences from PBMC and VC virus,
presented in this report, along with previously published
sequences of P and VS viruses (Tirado et al., 2004). The
phylogenetic trees and distance matrices are shown in Fig.
1. In 3 of 5 individuals the VC virus was more closely97 104 109 112 117 119 122 123 125 134
P K L G S P E D R S
– – L – – P K – R –
– – L – – P K – R SG
P – – – S – K – – –
– – L – – – K – R –
P – – – S – E – – –
– – – – S – E – – –
– – L – S – – – – –
– – L G – – – G – –
– K L – – – K – – –
– – L – – – K – – –
200 203 204 207 209 211 213 214 218 220
T E E Q L R G L D K
– – E Q L K – F – K
– – E Q L K – F – K
– – E – – – – – D –
– – – – – – – – – –
A E E QE L K G F – –
A E E – – K – – – –
– – E – L – – – – –
TA K E E – K G F – –
– – E – – – G L – –
– – E – – – – L – –
41 57 58 60 61 64 65 68 69 72
R R Q D Q I E G H I
– – – – – M – – – –
– – E – – M – – – –
– – – – – – – – Q –
– – – – – – – – – –
– – – D – V – – – –
– – – D – V – – – –
– – – – – – – G – T
– K – E E – E – – –
K – – – – – – – – –
– – – – – – – – – –related with PBMC virus (nucleotide distance 0.1%–5.82%)
than the VS virus (1.24%–5.82%). The difference between
VC virus on one hand and PBMC and VS virus on the other
were statistically significant in Wilcoxon Rank Sum Test
(P b 0.05). Furthermore, the VS virus was identical to P
virus in 2 patients (004 and 41J) whereas it showed 3.51 and
1.24% disparity with VC virus, respectively. In another
patient (43L) the VS virus was again more closely
associated with P virus than with the VC virus (0.22 vs.
5.82% distance). In only one patient (36E) the VS virus was
more closely related with VC virus (4.77%) than P virus
(6.93%). Overall, our results suggest that cell-associated
viruses follow different evolutionary pathways compared to
that of cell-free virus in the same anatomical compartment
and cell-associated virus in female genital compartment are135 139 141 146 147 154 156 160 161
I T G Y N K S F Q
– T G – – – – F –
– – – – – – – F –
T – – – – – S – –
– – – – – – – – –
– – – Y – – – – Q
– – – – – – – – –
TI – – Y – – – – –
– – – – – – – F –
T – – – N K – – –
T – – – – – – – –
221 223 227 231 233 238 241 245 246
H K F G E L V V L
– – – E – – M –
– – F – – – – KMQL L
– K – – – – V – –
– – – – – – – – –
– – – – – – – – –
– – – – – – – – –
– – – G – – – – –
Q – – – – – – – –
– K – – – KT – – –
– K – – – – – – –
76 79 83 92 93 95 98 99
L P N Q I C N F
– – – – – – – –
– – – – – – – –
– – – – – – – –
– – – – – – N –
L – – – – C – –
L – – – – C – –
– – N Q – – – –
– – – – L – – –
– P – – L – N –
– – – – – – N –
Fig. 1. Phylogenetic reconstruction and nucleotide distance of viruses from 4 different compartments of 5 HIV-infected females. The pol sequences were
aligned using ClustalX and MEGA. The MEGA program was used to calculate distance matrices. Phylogenetic trees were generated with MEGA using
neighbor-joining method and the trees were visualized using TreeView program. P = Plasma virus; VS = Vaginal secretion virus; PBMC = Peripheral blood
mononuclear virus and VC = Vaginal cell virus.
G. Tirado et al. / Virology 334 (2005) 299–305304closer to the cell-associated in blood than to the cell-free
virus in the vaginal compartment.Materials and methods
Patient population and sample preparation
Five HIV-infected females were enrolled for this study.
An informed consent was obtained from each subject.
PBMC was separated by spinning the blood on Ficoll-
Hypaque. Vaginal samples were collected by using two
Dacron-tipped applicators and taking swabs from cervico-vaginal area. The swabs were vigorously washed in 2 ml of
R-10 (RPMI-1640, HEPES, and 10% human AB plasma) to
release the virus and loosen cells before being removed
from tubes. Vaginal cells were separated by centrifugation
followed by two washings in RPMI-1640.
DNA extraction, PCR and sequencing
HIV-1 proviral DNA was isolated from PBMC and VC,
using the QIAamp DNA Blood Kit (QIAGEN, Inc.,
California). A 1318 base pair fragment of the polymerase
(pol) gene was amplified using a modification of the
TruGene HIV-1 Genotyping Kit (Bayer Healthcare-Diag-
G. Tirado et al. / Virology 334 (2005) 299–305 305nostic Div.) protocol. The PCR condition included 94 8C for
3 min, followed by 20 cycles of 94 8C for 30 s, 57 8C for
30 s, 72 8C for 1.5 min, then followed by 15 cycles of 94 8C
for 30 s, 60 8C for 30 s, and 70 8C for 2 min, with a final
extension of 70 8C for 7 min. Sequencing reactions were
performed according to manufacturer’s instructions. Bi-
directional sequences of the protease (pro) gene (codons 1–
99) and most of the reverse transcriptase (RT) gene (codons
39–247) were detected with the OpenGene System (Bayer
Healthcare-Diagnostic Div.). The resistance pattern was
generated using Guidelines 8.0 (updated April 2003),
provided by the supplier.
Computational analysis
The pol sequences from PBMC, VC, P and VS viruses
were analyzed for their relatedness with each other. The
sequences for the 1st 2 viruses were taken from this study
and the P and VS virus from our previously reported study
(Tirado et al., 2004). The pol sequences were aligned with
BioEdit version 5.0.9 (Hall, 1999) and ClustalX (Thompson
et al., 1997). The ClustalX program was set to perform
multiple sequence alignments using the default penalties,
IUB DNA weigh matrix and unweighted transitions.
Sequence alignments were manually verified and edited if
necessary. Phylogenetic reconstructions were generated by
the Neighbour-Joining (NJ) method (Saitou and Nei, 1987),
and the trees were visualized using the TreeView program.
The distance matrices were calculated using MEGA version
2.1 (Kumar et al., 2001). Genetic distances between
different compartment were statistically analyzed using
Wilcoxon Rank Sum Test.Acknowledgments
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